Pharmacokinetics in photodynamic therapy

Reviews in Contemporary Pharmacotherapy

Volumn 10, Issue 1, 1999, Pages 39-46

  Ronn, A M ^a,b  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; MACROGOL; PHOTOSENSITIZING AGENT; POLYETHYLENEGLYCOL TEMOPORFIN; TEMOPORFIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; NONHUMAN; PHOTODYNAMIC THERAPY; RABBIT;

EID: 0032911225     PISSN: 09548602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Bonnett R. Photosensitizers of the porphyrin and phthalocyanine series for photodynamic therapy. Chem Soc Rev 1995; 24: 19-33.
2. Korbelik M, Krosl G. Cellular levels of photosensitizers in tumours: the role of proximity to the blood supply. Br J Cancer 1994; 70: 604-610.
3. Kreider JW, Bartlett GL. The Shope papilloma-carcinoma complex of rabbits: a model system of neoplastic progression and spontaneous regression. Adv Cancer Res 1981; 35: 81-110.
4. Lofgren LA, Ronn AM, Abramson AL et al. Photodynamic therapy using mesotetra (hydroxyphenyl) chlorin: an animal model. Arch Otolaryngol Head Neck Surg 1994; 120: 1355-1362.
5. Lofgren LA, Ronn AM, Nouri M, Lee CJ, Yoo D, Steinberg BM. Efficacy of intravenous δ-aminolaevulinic acid photodynamic therapy on rabbit papillomas. Br J Cancer 1995; 72: 857-864.
6. Mason MD. Cellular aspects of photodynamic therapy for cancer. Rev Contemp Pharmacother 1999; 10: 25-37.
7. Ronn AM, Nouri M, Lofgren LA et al. Human tissue levels and plasma pharmacokinetics of temoporfin(Foscan®, mTHPC). Lasers Med Sci 1996; 11: 267-272.
8. Ronn AM, Batti J, Lee CJ et al. Comparative biodistribution of meta-Tetra (Hydroxyphenyl) chlorin in multiple species: clinical implications for photodynamic therapy. Lasers Surg Med 1997; 20: 437-442.
9. Ronn AM, Nouri M, Pecci F, Abramson AL. Evaluation of the photosensitizing third generation drug SC 102 aka tetrakis-(methoxypolyethylene glycol [MW 2000] in two animal models. Lasers Surg Med Suppl 1998; 10: 29.
10. Ronn AM, Nouri M, Pecci F, Abramson AL, Yeo N. Pharmacokinetics, biodistribution and efficacy of photodynamic therapy with PEG-temoporfin derivative in the rabbit and dog models. Lasers Med Sci 1999, in press.
11. Rous P, Beard JW. The progression to carcinoma of virus-induced rabbit papillomas (Shope). J Exp Med 1935; 62: 523-548.
12. Syverton JT. The pathogenesis of the rabbit papilloma-to-carcinoma sequence. Ann N Y Acad Sci 1952; 54: 1441-1446.
13. von Tappiener H, Jesionek A. Therapeutische Veriche mit fluoreszierenden Stoffen. Munch Med Wochenschr 1903; 50: 2042-2044.
14. Westermann P, Glanzman S, Andrejevic S et al. Long circulating half-life and high tumor selectivity of the photosensitizer meta-tetrahydroxyphenylchlorine conjugated to polyethylene glycol in nude mice grafted with a human colon carcinoma. Int J Cancer 1998; 76: 842-850.